Literature for E64d (C01.001 inhibitor)

(Topics flags: I Inhibitor, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Wang,Y., Xu,C., Ma,L., Mou,Y., Zhang,B., Zhou,S., Tian,Y., Trinh,J., Zhang,X. and Li,X.J.
   Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
   Life Sci Alliance2, PubMed  Europe PubMed DOI  I
2015
2. Hook,G., Jacobsen,J.S., Grabstein,K., Kindy,M. and Hook,V.
   Cathepsin B is a new drug target for traumatic brain injury therapeutics: evidence for E64d as a promising lead drug candidate
   Front Neurol6, 178-178. PubMed  Europe PubMed DOI  I
2014
3. Hook,G., Yu,J., Toneff,T., Kindy,M. and Hook,V.
   Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic
   J Alzheimers Dis41, 129-149. PubMed  Europe PubMed DOI  I
2011
4. Iguchi-Hashimoto,M., Usui,T., Yoshifuji,H., Shimizu,M., Kobayashi,S., Ito,Y., Murakami,K., Shiomi,A., Yukawa,N., Kawabata,D., Nojima,T., Ohmura,K., Fujii,T. and Mimori,T.
   Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-kappaB and increased STAT5 signals
   PLoS ONE6, e27020-e27020. PubMed  Europe PubMed DOI  U  I
1995
5. Kim,J.C., Spence,R.A., Currier,P.F., Lu,X. and Denison,M.R.
   Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d
   Virology208, 1-8. PubMed  Europe PubMed DOI  I